{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:00:38Z","timestamp":1790200838617,"version":"4.1.0"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoiotech.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immuno-Oncology and Technology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.iotech.2026.101615","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:57:45Z","timestamp":1790099865000},"page":"101615","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Why CD4+ T cells matter in adoptive cell therapy for solid cancers"],"prefix":"10.1016","volume":"32","author":[{"given":"S.","family":"Jegatheeson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3731-6204","authenticated-orcid":false,"given":"C.","family":"Scheffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"De Bondt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.K.","family":"Darcy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2729-5887","authenticated-orcid":false,"given":"P.J.","family":"Neeson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.iotech.2026.101615_bib1","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005755","volume":"10","author":"Chesney","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"23","key":"10.1016\/j.iotech.2026.101615_bib2","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","article-title":"Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma","volume":"387","author":"Rohaan","year":"2022","journal-title":"N Engl J Med"},{"issue":"6184","key":"10.1016\/j.iotech.2026.101615_bib3","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1126\/science.1251102","article-title":"Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer","volume":"344","author":"Tran","year":"2014","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.iotech.2026.101615_bib4","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41577-021-00539-6","article-title":"Cellular networks controlling T cell persistence in adoptive cell therapy","volume":"21","author":"Chan","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"10.1016\/j.iotech.2026.101615_bib5","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"10.1016\/j.iotech.2026.101615_bib6","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1016\/j.ymthe.2017.07.004","article-title":"Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy","volume":"25","author":"Kochenderfer","year":"2017","journal-title":"Mol Ther"},{"issue":"7","key":"10.1016\/j.iotech.2026.101615_bib7","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.ccell.2025.06.002","article-title":"Large B cell lymphoma microenvironment archetype profiles","volume":"43","author":"Li","year":"2025","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.iotech.2026.101615_bib8","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41573-021-00189-2","article-title":"Navigating CAR-T cells through the solid-tumour microenvironment","volume":"20","author":"Hou","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.iotech.2026.101615_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005878","article-title":"CD4 CAR-T cells targeting CD19 play a key role in exacerbating cytokine release syndrome, while maintaining long-term responses","volume":"11","author":"Bove","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.iotech.2026.101615_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030229","article-title":"Ex vivo expansion of human CD8+ T cells using autologous CD4+ T cell help","volume":"7","author":"Butler","year":"2012","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.iotech.2026.101615_bib11","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nri1413","article-title":"Helping the CD8+ T-cell response","volume":"4","author":"Bevan","year":"2004","journal-title":"Nat Rev Immunol"},{"issue":"7967","key":"10.1016\/j.iotech.2026.101615_bib12","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/s41586-023-06199-x","article-title":"CD4+ T cell-induced inflammatory cell death controls immune-evasive tumours","volume":"618","author":"Kruse","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.iotech.2026.101615_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.867189","article-title":"The era of cytotoxic CD4 T cells","volume":"13","author":"Cenerenti","year":"2022","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.iotech.2026.101615_bib14","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1158\/2326-6066.CIR-13-0068","article-title":"Enhancement of tumor-reactive cytotoxic CD4+ T-cell responses after ipilimumab treatment in four advanced melanoma patients","volume":"1","author":"Kitano","year":"2013","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"10.1016\/j.iotech.2026.101615_bib15","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1002\/eji.201041120","article-title":"Killing of myeloid APCs via HLA class I, CD2 and CD226 defines a novel mechanism of suppression by human Tr1 cells","volume":"41","author":"Magnani","year":"2011","journal-title":"Eur J Immunol"},{"issue":"8023","key":"10.1016\/j.iotech.2026.101615_bib16","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s41586-024-07752-y","article-title":"Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapy","volume":"632","author":"Sultan","year":"2024","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.iotech.2026.101615_bib17","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1182\/blood-2006-02-002774","article-title":"Regulatory T cells in cancer","volume":"108","author":"Beyer","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.iotech.2026.101615_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.669474","article-title":"Differentiation and regulation of TH cells: a balancing act for cancer immunotherapy","volume":"12","author":"Basu","year":"2021","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.iotech.2026.101615_bib19","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41577-018-0044-0","article-title":"CD4+ T cell help in cancer immunology and immunotherapy","volume":"18","author":"Borst","year":"2018","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"10.1016\/j.iotech.2026.101615_bib20","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/s43018-023-00521-2","article-title":"CD4+ T cells in cancer","volume":"4","author":"Speiser","year":"2023","journal-title":"Nat Cancer"},{"issue":"3","key":"10.1016\/j.iotech.2026.101615_bib21","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1158\/0008-5472.CAN-14-2748","article-title":"Th9 Cells: A novel CD4 T-cell subset in the immune war against cancer","volume":"75","author":"V\u00e9gran","year":"2015","journal-title":"Cancer Res"},{"issue":"16","key":"10.1016\/j.iotech.2026.101615_bib22","doi-asserted-by":"crossref","first-page":"5343","DOI":"10.1158\/1078-0432.CCR-11-0503","article-title":"Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice","volume":"17","author":"Klebanoff","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.iotech.2026.101615_bib23","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.4049\/jimmunol.167.8.4286","article-title":"Regression of extensive pulmonary metastases in mice by adoptive transfer of antigen-specific CD8+ CTL reactive against tumor cells expressing a naturally occurring rejection epitope","volume":"167","author":"Ryan","year":"2001","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.iotech.2026.101615_bib24","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1158\/0008-5472.CAN-04-3169","article-title":"Adoptive transfer of tumor-reactive transforming growth factor-\u03b2\u2013insensitive CD8+ T cells: eradication of autologous mouse prostate cancer","volume":"65","author":"Zhang","year":"2005","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.iotech.2026.101615_bib25","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1158\/1078-0432.CCR-09-1758","article-title":"Immunotherapy for human renal cell carcinoma by adoptive transfer of autologous transforming growth factor \u03b2\u2013insensitive CD8+ T cells","volume":"16","author":"Wang","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"31","key":"10.1016\/j.iotech.2026.101615_bib26","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.1200\/JCO.2006.07.1100","article-title":"Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma","volume":"24","author":"Mackensen","year":"2006","journal-title":"J Clin Oncol"},{"issue":"7655","key":"10.1016\/j.iotech.2026.101615_bib27","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nature22367","article-title":"Chromatin states define tumour-specific T cell dysfunction and reprogramming","volume":"545","author":"Philip","year":"2017","journal-title":"Nature"},{"issue":"6522","key":"10.1016\/j.iotech.2026.101615_bib28","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1126\/science.abb9847","article-title":"Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer","volume":"370","author":"Krishna","year":"2020","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.iotech.2026.101615_bib29","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/eji.201343718","article-title":"Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells","volume":"44","author":"Church","year":"2014","journal-title":"Eur J Immunol"},{"issue":"6","key":"10.1016\/j.iotech.2026.101615_bib30","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002157","article-title":"Follicular helper-T cells restore CD8+-dependent antitumor immunity and anti-PD-L1\/PD-1 efficacy","volume":"9","author":"Niogret","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.iotech.2026.101615_bib31","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1084\/jem.20091918","article-title":"Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts","volume":"207","author":"Quezada","year":"2010","journal-title":"J Exp Med"},{"issue":"7","key":"10.1016\/j.iotech.2026.101615_bib32","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.cell.2023.03.007","article-title":"T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants","volume":"186","author":"Hirschhorn","year":"2023","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.iotech.2026.101615_bib33","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.ccell.2021.09.011","article-title":"Adoptive cell therapy with tumor-specific Th9 cells induces viral mimicry to eliminate antigen-loss-variant tumor cells","volume":"39","author":"Xue","year":"2021","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.iotech.2026.101615_bib34","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1182\/blood-2004-12-4906","article-title":"Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejection","volume":"106","author":"Moeller","year":"2005","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.iotech.2026.101615_bib35","doi-asserted-by":"crossref","first-page":"11428","DOI":"10.1158\/0008-5472.CAN-07-1141","article-title":"Sustained antigen-specific antitumor recall response mediated by gene-modified CD4+ T helper-1 and CD8+ T cells","volume":"67","author":"Moeller","year":"2007","journal-title":"J Cancer Res"},{"issue":"261","key":"10.1016\/j.iotech.2026.101615_bib36","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3010162","article-title":"Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity","volume":"6","author":"Adusumilli","year":"2014","journal-title":"Sci Transl Med"},{"issue":"10","key":"10.1016\/j.iotech.2026.101615_bib37","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.99048","article-title":"Glioblastoma-targeted CD4+ CAR T cells mediate superior antitumor activity","volume":"3","author":"Wang","year":"2018","journal-title":"JCI Insight"},{"issue":"690","key":"10.1016\/j.iotech.2026.101615_bib38","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abk1900","article-title":"TSTEM-like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical models","volume":"15","author":"Meyran","year":"2023","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.iotech.2026.101615_bib39","doi-asserted-by":"crossref","first-page":"16168","DOI":"10.1073\/pnas.242600099","article-title":"Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells","volume":"99","author":"Yee","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.iotech.2026.101615_bib40","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/00002371-200205000-00007","article-title":"A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma","volume":"25","author":"Dudley","year":"2002","journal-title":"J Immunother"},{"issue":"2","key":"10.1016\/j.iotech.2026.101615_bib41","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S1074-7613(00)00026-1","article-title":"Eradication of established tumors by CD8+ T cell adoptive immunotherapy","volume":"13","author":"Hanson","year":"2000","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.iotech.2026.101615_bib42","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/00002371-200107000-00012","article-title":"Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma","volume":"24","author":"Dudley","year":"2001","journal-title":"J Immunother"},{"issue":"25","key":"10.1016\/j.iotech.2026.101615_bib43","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1056\/NEJMoa0800251","article-title":"Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1","volume":"358","author":"Hunder","year":"2008","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.iotech.2026.101615_bib44","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1172\/JCI98689","article-title":"Tumor-infiltrating BRAFV600E-specific CD4+ T cells correlated with complete clinical response in melanoma","volume":"128","author":"Veatch","year":"2018","journal-title":"J Clin Invest"},{"issue":"17","key":"10.1016\/j.iotech.2026.101615_bib45","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1200\/JCO.2012.46.6441","article-title":"Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma","volume":"31","author":"Dudley","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.iotech.2026.101615_bib46","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/CCO.0000000000000925","article-title":"Novel strategies to improve efficacy of treatment with tumor-infiltrating lymphocytes (TILs) for patients with solid cancers","volume":"35","author":"Tas","year":"2023","journal-title":"Curr Opin Oncol"},{"issue":"5","key":"10.1016\/j.iotech.2026.101615_bib47","doi-asserted-by":"crossref","first-page":"735","DOI":"10.4049\/jimmunol.2300250","article-title":"CD4 phenotypes are associated with reduced expansion of tumor-infiltrating lymphocytes in melanoma patients treated with adoptive cell therapy","volume":"211","author":"Thompson","year":"2023","journal-title":"J Immunol"},{"issue":"10","key":"10.1016\/j.iotech.2026.101615_bib48","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007288","article-title":"Neoantigen-specific CD4+ tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients","volume":"11","author":"Hall","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"19","key":"10.1016\/j.iotech.2026.101615_bib49","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1158\/1078-0432.CCR-22-3853","article-title":"Uncoupling CD4+ TIL-mediated tumor killing from JAK-signaling in melanoma","volume":"29","author":"Draghi","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.iotech.2026.101615_bib50","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1084\/jem.20091921","article-title":"Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma","volume":"207","author":"Xie","year":"2010","journal-title":"J Exp Med"},{"issue":"5","key":"10.1016\/j.iotech.2026.101615_bib51","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/CJI.0b013e31825898c5","article-title":"Tumor-specific CD4+ melanoma tumor-infiltrating lymphocytes","volume":"35","author":"Friedman","year":"2012","journal-title":"J Immunother"},{"issue":"6","key":"10.1016\/j.iotech.2026.101615_bib52","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/icb.2016.14","article-title":"Tumour-specific CD4 T cells eradicate melanoma via indirect recognition of tumour-derived antigen","volume":"94","author":"Shklovskaya","year":"2016","journal-title":"Immunol Cell Biol"},{"issue":"29","key":"10.1016\/j.iotech.2026.101615_bib53","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1200\/JCO.2017.74.5463","article-title":"Treatment of patients with metastatic cancer using a major histocompatibility complex class II\u2013restricted T-cell receptor targeting the cancer germline antigen MAGE-A3","volume":"35","author":"Lu","year":"2017","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.iotech.2026.101615_bib54","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1158\/2326-6066.CIR-22-0040","article-title":"Adoptive cellular therapy with autologous tumor-infiltrating lymphocytes and T-cell receptor\u2013engineered T cells targeting common p53 neoantigens in human solid tumors","volume":"10","author":"Kim","year":"2022","journal-title":"Cancer Immunol Res"},{"issue":"7897","key":"10.1016\/j.iotech.2026.101615_bib55","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4+ CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.iotech.2026.101615_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1271236","article-title":"Cytotoxic CD4+ T cells in chronic viral infections and cancer","volume":"14","author":"Malyshkina","year":"2023","journal-title":"Front Immunol"},{"issue":"13","key":"10.1016\/j.iotech.2026.101615_bib57","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1182\/bloodadvances.2023012416","article-title":"CD4+ CAR T-cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR T-cell therapy","volume":"8","author":"Ledergor","year":"2024","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.iotech.2026.101615_bib58","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/s43018-023-00570-7","article-title":"Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-\u03b3 is a major determinant of CD4+ CAR T-cell antitumor activity","volume":"4","author":"Boulch","year":"2023","journal-title":"Nat Cancer"},{"issue":"11","key":"10.1016\/j.iotech.2026.101615_bib59","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007803","article-title":"CD8+ chimeric antigen receptor T cells manufactured in absence of CD4+ cells exhibit hypofunctional phenotype","volume":"11","author":"Lee","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.iotech.2026.101615_bib60","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"issue":"10254","key":"10.1016\/j.iotech.2026.101615_bib61","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"suppl 1","key":"10.1016\/j.iotech.2026.101615_bib62","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1182\/blood-2025-127","article-title":"Comparison of axi-cel versus liso-cel as 2nd line therapy for relapsed\/refractory large B-cell lymphoma in real-life: A lysa study from the descar-T registry","volume":"146","author":"Brisou","year":"2025","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.iotech.2026.101615_bib63","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1111\/febs.17326","article-title":"Depletion of Tregs from CD4+ CAR-T cells enhances the tumoricidal effect of CD8+ CAR-T cells in anti-CD19 CAR-T therapy","volume":"292","author":"Sun","year":"2025","journal-title":"FEBS J"},{"issue":"1","key":"10.1016\/j.iotech.2026.101615_bib64","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.immuni.2019.12.007","article-title":"Regulatory T cells restrain interleukin-2-and Blimp-1-dependent acquisition of cytotoxic function by CD4+ T cells","volume":"52","author":"\u015aledzi\u0144ska","year":"2020","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.iotech.2026.101615_bib65","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1084\/jem.20150519","article-title":"CRTAM determines the CD4+ cytotoxic T lymphocyte lineage","volume":"213","author":"Takeuchi","year":"2016","journal-title":"J Exp Med"},{"key":"10.1016\/j.iotech.2026.101615_bib66","series-title":"CD4+ T cells in antitumor immunity","author":"Montauti","year":"2024"},{"issue":"7","key":"10.1016\/j.iotech.2026.101615_bib67","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1038\/s41423-021-00712-w","article-title":"The two faces of IL-2: a key driver of CD8+ T-cell exhaustion","volume":"18","author":"Kwon","year":"2021","journal-title":"Cell Mol Immunol"},{"issue":"4","key":"10.1016\/j.iotech.2026.101615_bib68","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s11684-017-0543-6","article-title":"CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells","volume":"11","author":"Zhang","year":"2017","journal-title":"Front Med"},{"issue":"1","key":"10.1016\/j.iotech.2026.101615_bib69","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1038\/s41467-021-23331-5","article-title":"CRISPR\/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy","volume":"12","author":"Giuffrida","year":"2021","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.iotech.2026.101615_bib70","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133977","article-title":"TGF-\u03b2 inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors","volume":"5","author":"Tang","year":"2020","journal-title":"JCI Insight"},{"issue":"3","key":"10.1016\/j.iotech.2026.101615_bib71","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00262-018-2281-2","article-title":"CRISPR\/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions","volume":"68","author":"Hu","year":"2019","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.iotech.2026.101615_bib72","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41598-017-00462-8","article-title":"CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells","volume":"7","author":"Rupp","year":"2017","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.iotech.2026.101615_bib73","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ccell.2024.01.002","article-title":"Inosine induces stemness features in CAR-T cells and enhances potency","volume":"42","author":"Klysz","year":"2024","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.iotech.2026.101615_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2024.167346","article-title":"BCL6 overexpression in CD4+ T cells induces TFH-like transdifferentiation and enhances antitumor efficiency of CAR-T therapy in pancreatic cancer","volume":"1870","author":"Lin","year":"2024","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"5","key":"10.1016\/j.iotech.2026.101615_bib75","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1158\/2326-6066.CIR-18-0466","article-title":"IL15 enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype","volume":"7","author":"Alizadeh","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"10","key":"10.1016\/j.iotech.2026.101615_bib76","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1158\/2159-8290.CD-20-1554","article-title":"CDK4\/6 inhibition promotes antitumor immunity through the induction of T-cell memory","volume":"11","author":"Lelliott","year":"2021","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.iotech.2026.101615_bib77","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.ccell.2020.05.004","article-title":"Multi-phenotype CRISPR-Cas9 screen identifies p38 kinase as a target for adoptive immunotherapies","volume":"37","author":"Gurusamy","year":"2020","journal-title":"Cancer Cell"},{"issue":"8010","key":"10.1016\/j.iotech.2026.101615_bib78","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41586-024-07242-1","article-title":"FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy","volume":"629","author":"Chan","year":"2024","journal-title":"Nature"},{"issue":"8010","key":"10.1016\/j.iotech.2026.101615_bib79","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41586-024-07300-8","article-title":"FOXO1 is a master regulator of memory programming in CAR T cells","volume":"629","author":"Doan","year":"2024","journal-title":"Nature"}],"container-title":["Immuno-Oncology and Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590018826000341?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590018826000341?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:06:57Z","timestamp":1790197617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590018826000341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":79,"alternative-id":["S2590018826000341"],"URL":"https:\/\/doi.org\/10.1016\/j.iotech.2026.101615","relation":{},"ISSN":["2590-0188"],"issn-type":[{"value":"2590-0188","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Why CD4+ T cells matter in adoptive cell therapy for solid cancers","name":"articletitle","label":"Article Title"},{"value":"Immuno-Oncology and Technology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iotech.2026.101615","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101615"}}